JP2024010053A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024010053A5 JP2024010053A5 JP2023181425A JP2023181425A JP2024010053A5 JP 2024010053 A5 JP2024010053 A5 JP 2024010053A5 JP 2023181425 A JP2023181425 A JP 2023181425A JP 2023181425 A JP2023181425 A JP 2023181425A JP 2024010053 A5 JP2024010053 A5 JP 2024010053A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variant
- fragment
- lysin polypeptide
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 83
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 83
- 229920001184 polypeptide Polymers 0.000 claims description 74
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 74
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 54
- 230000002101 lytic effect Effects 0.000 claims description 42
- 241000894006 Bacteria Species 0.000 claims description 36
- 241000894007 species Species 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000588919 Citrobacter freundii Species 0.000 claims description 2
- 108010078777 Colistin Proteins 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- -1 aminoglycosides Chemical compound 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229960002100 cefepime Drugs 0.000 claims description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 2
- 229960004682 cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960000484 ceftazidime Drugs 0.000 claims description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 2
- 229950004259 ceftobiprole Drugs 0.000 claims description 2
- VOAZJEPQLGBXGO-SDAWRPRTSA-N ceftobiprole Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(\C=C/4C(N([C@H]5CNCC5)CC\4)=O)CS[C@@H]32)C(O)=O)=O)=N1 VOAZJEPQLGBXGO-SDAWRPRTSA-N 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229960003346 colistin Drugs 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 229960000895 doripenem Drugs 0.000 claims description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 229940118764 francisella tularensis Drugs 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 229960002182 imipenem Drugs 0.000 claims description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960002260 meropenem Drugs 0.000 claims description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 229960002292 piperacillin Drugs 0.000 claims description 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims description 2
- 229920000024 polymyxin B Polymers 0.000 claims description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 2
- 229960005266 polymyxin b Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 229960001225 rifampicin Drugs 0.000 claims description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229960004659 ticarcillin Drugs 0.000 claims description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 2
- 229960000707 tobramycin Drugs 0.000 claims description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 2
- 241000588626 Acinetobacter baumannii Species 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 101710126949 Lysin Proteins 0.000 description 37
- 238000000034 method Methods 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597577P | 2017-12-12 | 2017-12-12 | |
| US62/597,577 | 2017-12-12 | ||
| US201862721969P | 2018-08-23 | 2018-08-23 | |
| US62/721,969 | 2018-08-23 | ||
| PCT/US2018/065265 WO2019118632A1 (en) | 2017-12-12 | 2018-12-12 | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| JP2020531748A JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531748A Division JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024010053A JP2024010053A (ja) | 2024-01-23 |
| JP2024010053A5 true JP2024010053A5 (enExample) | 2024-08-29 |
| JP7646237B2 JP7646237B2 (ja) | 2025-03-17 |
Family
ID=66819724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531748A Pending JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
| JP2023181425A Active JP7646237B2 (ja) | 2017-12-12 | 2023-10-20 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531748A Pending JP2021506769A (ja) | 2017-12-12 | 2018-12-12 | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12121568B2 (enExample) |
| EP (1) | EP3723789A4 (enExample) |
| JP (2) | JP2021506769A (enExample) |
| KR (1) | KR20200098615A (enExample) |
| CN (1) | CN111971058A (enExample) |
| AU (1) | AU2018384790C1 (enExample) |
| BR (1) | BR112020011433A2 (enExample) |
| CA (1) | CA3085644A1 (enExample) |
| IL (2) | IL303122A (enExample) |
| MX (1) | MX2020006098A (enExample) |
| WO (1) | WO2019118632A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020011433A2 (pt) | 2017-12-12 | 2020-12-01 | Contrafect Corporation | identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa |
| WO2019126670A1 (en) * | 2017-12-22 | 2019-06-27 | The Rockefeller University | Recombinant pseudomonas aeruginosa lysins |
| CN112368376A (zh) | 2018-03-29 | 2021-02-12 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
| US10988520B2 (en) * | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| WO2020046747A1 (en) * | 2018-08-23 | 2020-03-05 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3946609A4 (en) * | 2019-04-05 | 2023-05-03 | Contrafect Corporation | LYSINE AND ITS DERIVATIVES WITH BACTERICIDAL ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA IN THE PRESENCE OF HUMAN SERUM |
| KR102225240B1 (ko) * | 2019-07-03 | 2021-03-10 | 경북대학교 산학협력단 | 다제내성 병원성 세균을 효과적으로 사멸시키는 재조합 항균 단백질 Ablysin의 용도 |
| US20220411473A1 (en) * | 2019-11-14 | 2022-12-29 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| WO2023034646A2 (en) * | 2021-09-03 | 2023-03-09 | Aanika Biosciences, Inc. | Lysecd7 variants and methods of using the same |
| CN114410670B (zh) * | 2022-01-29 | 2024-01-23 | 福建医科大学附属口腔医院 | 一种溶菌酶及其在口腔护理用品中的应用 |
| CN117660413B (zh) * | 2023-12-15 | 2024-06-07 | 华南理工大学 | 一种内溶素Lys009及其工程改造和应用 |
| CN120173923A (zh) * | 2025-05-08 | 2025-06-20 | 浙江大学 | 与PeiR裂解酶高维特征同源的产甲烷菌裂解酶及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| JP5701777B2 (ja) | 2009-02-06 | 2015-04-15 | テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| CA2780079A1 (en) | 2009-11-18 | 2011-05-26 | Basf Plant Science Company Gmbh | Process for the production of fine chemicals |
| EA037276B1 (ru) | 2010-04-27 | 2021-03-03 | Лисандо Аг | Способы устранения или уменьшения бактериальной биопленки |
| GB201018518D0 (en) | 2010-11-03 | 2010-12-15 | Univ Leuven Kath | Novel endolysin |
| CA2833409A1 (en) | 2011-04-21 | 2012-10-26 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
| WO2015070912A1 (en) | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
| AU2015279705B2 (en) | 2014-06-26 | 2021-04-01 | The Rockefeller University | Acinetobacter lysins |
| AU2016324307B2 (en) * | 2015-09-17 | 2021-10-21 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| BR112020011433A2 (pt) | 2017-12-12 | 2020-12-01 | Contrafect Corporation | identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa |
| CN108103050A (zh) | 2018-02-11 | 2018-06-01 | 中国医药集团总公司四川抗菌素工业研究所 | 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用 |
| CN112368376A (zh) | 2018-03-29 | 2021-02-12 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
| WO2020046747A1 (en) | 2018-08-23 | 2020-03-05 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
-
2018
- 2018-12-12 BR BR112020011433-2A patent/BR112020011433A2/pt not_active Application Discontinuation
- 2018-12-12 EP EP18889220.2A patent/EP3723789A4/en not_active Withdrawn
- 2018-12-12 AU AU2018384790A patent/AU2018384790C1/en active Active
- 2018-12-12 JP JP2020531748A patent/JP2021506769A/ja active Pending
- 2018-12-12 WO PCT/US2018/065265 patent/WO2019118632A1/en not_active Ceased
- 2018-12-12 CN CN201880089186.9A patent/CN111971058A/zh active Pending
- 2018-12-12 MX MX2020006098A patent/MX2020006098A/es unknown
- 2018-12-12 US US16/772,001 patent/US12121568B2/en active Active
- 2018-12-12 KR KR1020207020090A patent/KR20200098615A/ko not_active Ceased
- 2018-12-12 CA CA3085644A patent/CA3085644A1/en active Pending
- 2018-12-12 IL IL303122A patent/IL303122A/en unknown
- 2018-12-12 IL IL275060A patent/IL275060B2/en unknown
-
2023
- 2023-10-20 JP JP2023181425A patent/JP7646237B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024010053A5 (enExample) | ||
| JP2021519083A5 (enExample) | ||
| IL277119B1 (en) | Antimicrobial lysine-peptide polypeptide templates, lysines, isolated polynucleotides encoding them and uses thereof | |
| RU2018107245A (ru) | Полипептиды лизина, активные против грамотрицательных бактерий | |
| JP2021506769A5 (enExample) | ||
| JP7646237B2 (ja) | シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定 | |
| JP2021533728A5 (enExample) | ||
| JP2022526978A5 (enExample) | ||
| JP2023502940A5 (enExample) | ||
| JP2022526978A (ja) | ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体 | |
| RU2020131450A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий | |
| RU2021137156A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных и кислотоустойчивых бактерий | |
| WO2023049243A1 (en) | Lysostaphin variants and methods of use thereof | |
| RU2021128336A (ru) | Лизины и их производные с бактерицидной активностью против pseudomonas aeruginosa в присутствии сыворотки крови человека | |
| US12606640B2 (en) | Recombinant antimicrobial multidomain polypeptide, methods of producing and uses thereof | |
| HK40086790A (en) | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby | |
| JP2023513934A5 (enExample) |